XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
PR Newswire - Mon Dec 08, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 58.39 (+0.07), XTLB: 2.21 (+0.03)
XTL Biopharma Q3 results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:21AM CST
XTLB: 2.21 (+0.03)
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014
PR Newswire - Mon Dec 01, 7:00AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 58.39 (+0.07), XTLB: 2.21 (+0.03)
XTL Biopharmaceuticals EPS of $0
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:34AM CST
XTLB: 2.21 (+0.03)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.61 (unch), NEO: 4.03 (-0.10), AU: 8.39 (+0.24), FNHC: 25.30 (+0.45), AMS: 2.50 (-0.02), NYMX: 0.38 (unch), AMDA: 0.64 (-0.01), CVD: 103.73 (+0.02), GBIM: 7.29 (unch), RCAP: 11.23 (+0.26), KBIO: 1.63 (-0.04), COOL: 1.15 (+0.14), SAPE: 24.81 (-0.01), XTLB: 2.21 (+0.03), GERN: 3.06 (+0.05), ANIP: 55.24 (+1.79), BBLU: 1.15 (-0.03), NXTD: 2.46 (-0.09), AP: 19.03 (+0.47), ALQA: 3.96 (-0.02)
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
PR Newswire - Tue Sep 02, 11:09AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 58.39 (+0.07), XTLB: 2.21 (+0.03)
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
PR Newswire - Wed Jul 16, 8:18AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 58.39 (+0.07), XTLB: 2.21 (+0.03)
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
PR Newswire - Thu Jun 12, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"
XTL: 58.39 (+0.07), XTLB: 2.21 (+0.03)